Literature DB >> 34843387

Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock.

Mariana Chumbita1, Pedro Puerta-Alcalde1, Carlota Gudiol2,3,4, Nicole Garcia-Pouton1, Júlia Laporte-Amargós2,4, Andrea Ladino5, Adaia Albasanz-Puig2,4, Cristina Helguera6, Alba Bergas2, Ignacio Grafia5, Enric Sastre2, María Suárez-Lledó7, Xavier Durà2,4, Carlota Jordán1, Francesc Marco8,9, Maria Condom10, Pedro Castro11, Jose A Martínez1, Josep Mensa1, Alex Soriano1, Jordi Carratalà2,4, Carolina Garcia-Vidal1.   

Abstract

We analyzed risk factors for mortality in febrile neutropenic patients with bloodstream infections (BSI) presenting with septic shock and assessed the impact of empirical antibiotic regimens. A multicenter retrospective study (2010 to 2019) of two prospective cohorts compared BSI episodes in patients with or without septic shock. Multivariate analysis was performed to identify independent risk factors for mortality in episodes with septic shock. Of 1,563 patients with BSI, 257 (16%) presented with septic shock. Those patients with septic shock had higher mortality than those without septic shock (55% versus 15%, P < 0.001). Gram-negative bacilli caused 81% of episodes with septic shock, Gram-positive cocci caused 22%, and Candida species caused 5%. Inappropriate empirical antibiotic treatment (IEAT) was administered in 17.5% of septic shock episodes. Empirical β-lactam combined with other active antibiotics was associated with the lowest mortality observed. When amikacin was the only active antibiotic, mortality was 90%. Addition of empirical specific Gram-positive coverage had no impact on mortality. Mortality was higher when IEAT was administered (76% versus 51%, P = 0.002). Age of >70 years (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.2 to 4.7), IEAT for Candida spp. or Gram-negative bacilli (OR, 3.8; 95% CI, 1.3 to 11.1), acute kidney injury (OR, 2.6; 95% CI, 1.4 to 4.9), and amikacin as the only active antibiotic (OR, 15.2; 95% CI, 1.7 to 134.5) were independent risk factors for mortality, while the combination of β-lactam and amikacin was protective (OR, 0.32; 95% CI, 0.18 to 0.57). Septic shock in febrile neutropenic patients with BSI is associated with extremely high mortality, especially when IEAT is administered. Combination therapy including an active β-lactam and amikacin results in the best outcomes.

Entities:  

Keywords:  bacteremia; empirical treatment; mortality; neutropenia; shock

Mesh:

Substances:

Year:  2021        PMID: 34843387      PMCID: PMC8846468          DOI: 10.1128/AAC.01744-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  37 in total

1.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

2.  Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategies.

Authors:  P Puerta-Alcalde; C Cardozo; M Suárez-Lledó; O Rodríguez-Núñez; L Morata; C Fehér; F Marco; A Del Río; J A Martínez; J Mensa; M Rovira; J Esteve; A Soriano; C Garcia-Vidal
Journal:  Clin Microbiol Infect       Date:  2018-08-07       Impact factor: 8.067

3.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

4.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Authors:  G P Bodey; M Buckley; Y S Sathe; E J Freireich
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

5.  Sepsis and Septic Shock in Patients With Malignancies: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study.

Authors:  Virginie Lemiale; Stéphanie Pons; Adrien Mirouse; Jean-Jacques Tudesq; Yannick Hourmant; Djamel Mokart; Frédéric Pène; Achille Kouatchet; Julien Mayaux; Martine Nyunga; Fabrice Bruneel; Anne-Pascale Meert; Edith Borcoman; Magali Bisbal; Matthieu Legrand; Dominique Benoit; Elie Azoulay; Michaël Darmon; Lara Zafrani
Journal:  Crit Care Med       Date:  2020-06       Impact factor: 7.598

6.  Bloodstream infection-associated sepsis and septic shock in critically ill adults: a population-based study.

Authors:  K B Laupland; H D Davies; D L Church; T J Louie; J S Dool; D A Zygun; C J Doig
Journal:  Infection       Date:  2004-04       Impact factor: 3.553

7.  Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial.

Authors:  Manuela Aguilar-Guisado; Ildefonso Espigado; Almudena Martín-Peña; Carlota Gudiol; Cristina Royo-Cebrecos; José Falantes; Lourdes Vázquez-López; María Isabel Montero; Clara Rosso-Fernández; María de la Luz Martino; Rocío Parody; José González-Campos; Sebastián Garzón-López; Cristina Calderón-Cabrera; Pere Barba; Nancy Rodríguez; Montserrat Rovira; Enrique Montero-Mateos; Jordi Carratalá; José Antonio Pérez-Simón; José Miguel Cisneros
Journal:  Lancet Haematol       Date:  2017-11-15       Impact factor: 18.959

Review 8.  Invasive candidiasis as a cause of sepsis in the critically ill patient.

Authors:  Julie Delaloye; Thierry Calandra
Journal:  Virulence       Date:  2013-08-27       Impact factor: 5.882

9.  Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance.

Authors:  Carolina Garcia-Vidal; Celia Cardozo-Espinola; Pedro Puerta-Alcalde; Francesc Marco; Adrian Tellez; Daiana Agüero; Francisco Romero-Santana; Marina Díaz-Beyá; Eva Giné; Laura Morata; Olga Rodríguez-Núñez; Jose Antonio Martinez; Josep Mensa; Jordi Esteve; Alex Soriano
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

10.  Aetiology of bacteraemia as a risk factor for septic shock at the onset of febrile neutropaenia in adult cancer patients.

Authors:  Regis Goulart Rosa; Luciano Zubaran Goldani
Journal:  Biomed Res Int       Date:  2014-03-20       Impact factor: 3.411

View more
  1 in total

1.  Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia.

Authors:  Adaia Albasanz-Puig; Xavier Durà-Miralles; Júlia Laporte-Amargós; Alberto Mussetti; Isabel Ruiz-Camps; Pedro Puerta-Alcalde; Edson Abdala; Chiara Oltolini; Murat Akova; José Miguel Montejo; Malgorzata Mikulska; Pilar Martín-Dávila; Fabián Herrera; Oriol Gasch; Lubos Drgona; Hugo Manuel Paz Morales; Anne-Sophie Brunel; Estefanía García; Burcu Isler; Winfried V Kern; Pilar Retamar-Gentil; José María Aguado; Milagros Montero; Souha S Kanj; Oguz R Sipahi; Sebnem Calik; Ignacio Márquez-Gómez; Jorge I Marin; Marisa Z R Gomes; Philipp Hemmati; Rafael Araos; Maddalena Peghin; José Luis Del Pozo; Lucrecia Yáñez; Robert Tilley; Adriana Manzur; Andres Novo; Natàlia Pallarès; Alba Bergas; Jordi Carratalà; Carlota Gudiol
Journal:  Microorganisms       Date:  2022-03-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.